Optus Pharmaceutical applies for Korean MFDS approval for presbyopia treatment 'Clothy'
Predicted impact: Low
Presbyterian drug approval filing already reported; commercialization is targeted for 2028
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.